{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:21:05Z","timestamp":1757704865386,"version":"3.37.3"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004486","name":"Fondazione Cassa di Risparmio di Perugia","doi-asserted-by":"publisher","award":["2015.0363.021"],"award-info":[{"award-number":["2015.0363.021"]}],"id":[{"id":"10.13039\/501100004486","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.thromres.2019.01.005","type":"journal-article","created":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T22:17:02Z","timestamp":1547158622000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Inhibition of platelet function after ocular administration of non-steroidal anti-inflammatory drugs"],"prefix":"10.1016","volume":"175","author":[{"given":"Emanuela","family":"Falcinelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Mezzasoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavinia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Fierro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Guglielmini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Cagini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5365-8445","authenticated-orcid":false,"given":"Paolo","family":"Gresele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2019.01.005_bb0005","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0140-6736(17)30544-5","article-title":"Cataracts","volume":"390","author":"Liu","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2019.01.005_bb0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0886-3350(13)80481-6","article-title":"Causes of decreased visual acuity after cataract extraction","volume":"21","author":"Drolsum","year":"1995","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.thromres.2019.01.005_bb0015","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ajo.2015.07.032","article-title":"Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta-analysis","volume":"160","author":"Wielders","year":"2015","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0020","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ajo.2017.01.006","article-title":"Perioperative topical nonsteroidal anti-inflammatory drugs for macular edema prophylaxis following cataract surgery","volume":"176","author":"Modjtahedi","year":"2017","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/ICU.0000000000000436","article-title":"Prevention of macular edema after cataract surgery","volume":"29","author":"Wielders","year":"2018","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0030","first-page":"CD004239","article-title":"Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery","volume":"1","author":"Sivaprasad","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.thromres.2019.01.005_bb0035","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/02713683.2017.1396615","article-title":"Comparison of the Efficacy of Dexamethasone, Nepafenac, and Bromfenac for Preventing Pseudophakic Cystoid Macular Edema: an Open-label, Prospective, Randomized Controlled Trial","volume":"43","author":"Campa","year":"2018","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.thromres.2019.01.005_bb0040","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/bjo.2005.073817","article-title":"Non-steroidal anti-inflammatory agents for cystoid macular edema following cataract surgery: a systematic review","volume":"89","author":"Sivaprasad","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0045","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/j.1755-3768.2012.02520.x","article-title":"Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery","volume":"91","author":"Weber","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0050","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.ophtha.2014.04.035","article-title":"Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review","volume":"121","author":"Kessel","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.thromres.2019.01.005_bb0055","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1001\/jamaophthalmol.2015.0325","article-title":"Cardiovascular adverse effects of phenylephrine eyedrops: a systematic review and meta-analysis","volume":"133","author":"Stavert","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/00365510601034736","article-title":"Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects","volume":"67","author":"Nieminen","year":"2007","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.thromres.2019.01.005_bb0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1034\/j.1600-0420.1999.770215.x","article-title":"Systemic bioavailability of ocularly applied 1% atropine eyedrops","volume":"77","author":"Kaila","year":"1999","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.thromres.2019.01.005_bb0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1067\/mpd.2001.111319","article-title":"Ophthalmic drops causing coma in an infant","volume":"138","author":"Berlin","year":"2001","journal-title":"J. Pediatr."},{"key":"10.1016\/j.thromres.2019.01.005_bb0075","first-page":"3238","article-title":"ESC thrombosis working group. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on thrombosis","volume":"36","author":"Andreotti","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2019.01.005_bb0080","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.mcna.2014.11.012","article-title":"Antithrombotic management of atrial fibrillation in the elderly","volume":"99","author":"Edholm","year":"2015","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.thromres.2019.01.005_bb0085","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.thromres.2017.05.015","article-title":"Venous thromboembolism in the elderly: a narrative review","volume":"155","author":"Tritschler","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2019.01.005_bb0090","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/106002809502901214","article-title":"Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance","volume":"29","author":"Chan","year":"1995","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.thromres.2019.01.005_bb0095","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cpt.794","article-title":"Cyclooxygenase inhibition: pain, inflammation and the cardiovascular system","volume":"102","author":"Grosser","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.thromres.2019.01.005_bb0100","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1160\/TH12-07-0504","article-title":"In vivo platelet activation and platelet hyperreactivity in abacavir\u2013treated HIV\u2013infected patients","volume":"110","author":"Falcinelli","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.01.005_bb0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/09537104.2010.543710","article-title":"Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin","volume":"22","author":"Crescente","year":"2011","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2019.01.005_bb0110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2018.04.052","article-title":"Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients","volume":"263","author":"Falcinelli","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0115","first-page":"301","article-title":"Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders","volume":"246","author":"Gresele","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.thromres.2019.01.005_bb0120","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0735-1097(02)02972-8","article-title":"Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus","volume":"41","author":"Gresele","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0125","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.thromres.2006.11.012","article-title":"Measuring antiplatelet drug effects in the laboratory","volume":"120","author":"Harrison","year":"2007","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2019.01.005_bb0130","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.bbalip.2014.09.016","article-title":"Cyclooxygenase inhibitors: from pharmacology to clinical read-outs","volume":"1851","author":"Patrignani","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.thromres.2019.01.005_bb0135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/MJT.0b013e3182459abd","article-title":"Topical nonsteroidal anti-inflammatory drugs: the importance of drug, delivery, and therapeutic outcome","volume":"22","author":"Barkin","year":"2015","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.thromres.2019.01.005_bb0140","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1055\/s-0038-1657598","article-title":"Mechanisms initiating platelet thrombus formation","volume":"78","author":"Ruggeri","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.01.005_bb0145","article-title":"Platelet function assays in diagnosis: an update","author":"Gresele","year":"2018","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0150","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1160\/TH12-03-0212","article-title":"Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome","volume":"109","author":"Bontadi","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.01.005_bb0155","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1160\/TH12-08-0550","article-title":"Biomarkers of platelet activation in acute coronary syndromes","volume":"108","author":"Ferroni","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.01.005_bb0160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2019.01.005_bb0165","first-page":"661","article-title":"COX-2 is not involved in thromboxane biosynthesis by activated human platelets","volume":"50","author":"Patrignani","year":"1999","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02713680490513164","article-title":"Involvement of cyclooxygenase-2 in rat models of conjunctivitis","volume":"29","author":"Oka","year":"2004","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.thromres.2019.01.005_bb0175","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00417-017-3599-8","article-title":"The comparative efficacy and safety of topical non-steroidal anti-inflammatory drugs for the treatment of anterior chamber inflammation after cataract surgery: a systematic review and network meta-analysis","volume":"255","author":"Duan","year":"2017","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0180","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/IAE.0000000000000860","article-title":"Reduction of vitreous prostaglandin E2 levels after topical administration of indomethacin 0.5%, bromfenac 0.09%, and nepafenac 0.1","volume":"36","author":"Russo","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.thromres.2019.01.005_bb0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00001721-199901000-00004","article-title":"Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis","volume":"10","author":"Harrison","year":"1999","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2019.01.005_bb0190","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0090-6980(82)90123-X","article-title":"Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity","volume":"23","author":"Livio","year":"1982","journal-title":"Prostaglandins"},{"key":"10.1016\/j.thromres.2019.01.005_bb0195","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/1076029609338049","article-title":"Predisposing preventable factors in patients with bleeding due to warfarin usage: evaluation of 114 patients","volume":"16","author":"Beyan","year":"2010","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2019.01.005_bb0200","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1586\/14779072.2015.1071665","article-title":"Nonsteroidal anti-inflammatory drugs and bleeding risk in anticoagulated patients with atrial fibrillation","volume":"13","author":"Lip","year":"2015","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.thromres.2019.01.005_bb0205","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2125.2010.03827.x","article-title":"Warfarin-associated bleeding events and concomitant use of potentially interacting medicines reported to the Norwegian spontaneous reporting system","volume":"71","author":"Narum","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0210","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00228-010-0825-2","article-title":"Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly","volume":"66","author":"Vandraas","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0215","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/pds.2219","article-title":"Major bleeding risk associated with warfarin and co-medications in the elderly population","volume":"20","author":"Vitry","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.thromres.2019.01.005_bb0220","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2019.01.005_bb0225","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/bjo.73.9.702","article-title":"Warfarin and cataract extraction","volume":"73","author":"Robinson","year":"1989","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.thromres.2019.01.005_bb0230","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/archinte.163.8.901","article-title":"Perioperative management of patients receiving oral anticoagulants: a systematic review","volume":"163","author":"Dunn","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.thromres.2019.01.005_bb0235","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00002018-200225040-00002","article-title":"Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review","volume":"25","author":"Gaynes","year":"2002","journal-title":"Drug Saf."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819300143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819300143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T22:43:02Z","timestamp":1565217782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384819300143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":47,"alternative-id":["S0049384819300143"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2019.01.005","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of platelet function after ocular administration of non-steroidal anti-inflammatory drugs","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2019.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}